AU2004283235B2 - Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease - Google Patents
Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease Download PDFInfo
- Publication number
- AU2004283235B2 AU2004283235B2 AU2004283235A AU2004283235A AU2004283235B2 AU 2004283235 B2 AU2004283235 B2 AU 2004283235B2 AU 2004283235 A AU2004283235 A AU 2004283235A AU 2004283235 A AU2004283235 A AU 2004283235A AU 2004283235 B2 AU2004283235 B2 AU 2004283235B2
- Authority
- AU
- Australia
- Prior art keywords
- genotype
- pimecrolimus
- gene
- tnf
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50897103P | 2003-10-06 | 2003-10-06 | |
US60/508,971 | 2003-10-06 | ||
PCT/EP2004/011124 WO2005040416A1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004283235A1 AU2004283235A1 (en) | 2005-05-06 |
AU2004283235B2 true AU2004283235B2 (en) | 2007-08-02 |
Family
ID=34520002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004283235A Ceased AU2004283235B2 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070155772A1 (ja) |
EP (1) | EP1673473B1 (ja) |
JP (1) | JP2007507460A (ja) |
CN (1) | CN1890384A (ja) |
AT (1) | ATE515577T1 (ja) |
AU (1) | AU2004283235B2 (ja) |
BR (1) | BRPI0415302A (ja) |
CA (1) | CA2541138A1 (ja) |
ES (1) | ES2367566T3 (ja) |
MX (1) | MXPA06003828A (ja) |
PL (1) | PL1673473T3 (ja) |
PT (1) | PT1673473E (ja) |
WO (1) | WO2005040416A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2272544A1 (en) | 2003-03-28 | 2011-01-12 | Conor Medsystems, Inc. | Implantable medical device with beneficial agent concentration gradient |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
US20120283112A1 (en) | 2011-02-22 | 2012-11-08 | The Procter & Gamble Company | Systems and Methods for Identifying Cosmetic Agents for Skin Care Compositions |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
MX2013010977A (es) | 2011-03-31 | 2013-10-30 | Procter & Gamble | Sistema, modelos y metodos para identificar y evaluar agentes dermoactivos eficaces para tratar la caspa/dermatitis seborreica. |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
JP2015512260A (ja) | 2012-03-30 | 2015-04-27 | ザ プロクター アンド ギャンブルカンパニー | 皮膚色素沈着用の剤を決定する際に使用するためのデータ・アーキテクチャの構築方法 |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
MX2014014898A (es) | 2012-06-06 | 2015-03-04 | Procter & Gamble | Sistemas y metodos de identificacion de agentes cosmeticos para composiciones para el cuidado del cabello/cuero cabelludo. |
WO2014028568A1 (en) * | 2012-08-15 | 2014-02-20 | The Procter & Gamble Company | Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
ES2548793B1 (es) * | 2014-03-17 | 2016-07-07 | Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa | Método pronóstico de enfermedades autoinmunes mediante el genotipado de variantes genéticas del péptido intestinal vasoactivo |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
CN109476698B (zh) * | 2016-05-20 | 2023-10-17 | 西达-赛奈医疗中心 | 基于基因的炎性肠病诊断 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2647427B2 (ja) * | 1987-04-24 | 1997-08-27 | 帝人株式会社 | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット |
US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
WO2002089796A2 (en) * | 2001-05-09 | 2002-11-14 | Novartis Ag | Methods for selective immunomodulation using pimecrolimus |
-
2004
- 2004-10-05 EP EP04765831A patent/EP1673473B1/en active Active
- 2004-10-05 ES ES04765831T patent/ES2367566T3/es active Active
- 2004-10-05 MX MXPA06003828A patent/MXPA06003828A/es not_active Application Discontinuation
- 2004-10-05 WO PCT/EP2004/011124 patent/WO2005040416A1/en active IP Right Grant
- 2004-10-05 PL PL04765831T patent/PL1673473T3/pl unknown
- 2004-10-05 AU AU2004283235A patent/AU2004283235B2/en not_active Ceased
- 2004-10-05 US US10/574,770 patent/US20070155772A1/en not_active Abandoned
- 2004-10-05 CN CNA2004800358001A patent/CN1890384A/zh active Pending
- 2004-10-05 JP JP2006530098A patent/JP2007507460A/ja active Pending
- 2004-10-05 AT AT04765831T patent/ATE515577T1/de active
- 2004-10-05 PT PT04765831T patent/PT1673473E/pt unknown
- 2004-10-05 BR BRPI0415302-2A patent/BRPI0415302A/pt not_active IP Right Cessation
- 2004-10-05 CA CA002541138A patent/CA2541138A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070155772A1 (en) | 2007-07-05 |
AU2004283235A1 (en) | 2005-05-06 |
MXPA06003828A (es) | 2006-06-14 |
BRPI0415302A (pt) | 2006-12-05 |
JP2007507460A (ja) | 2007-03-29 |
CN1890384A (zh) | 2007-01-03 |
PL1673473T3 (pl) | 2011-12-30 |
CA2541138A1 (en) | 2005-05-06 |
ES2367566T3 (es) | 2011-11-04 |
EP1673473B1 (en) | 2011-07-06 |
ATE515577T1 (de) | 2011-07-15 |
PT1673473E (pt) | 2011-09-19 |
EP1673473A1 (en) | 2006-06-28 |
WO2005040416A1 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004283235B2 (en) | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease | |
EP2789695B1 (en) | Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs 10524523 | |
EP3507384B1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
JP2012507297A (ja) | Erbb4遺伝子の多型に基づく精神病及び統合失調症の治療法 | |
CN104937113B (zh) | 用于预测由基于抗精神病药物的治疗诱导的锥体外系症状(eps)的发病的方法 | |
US20050255498A1 (en) | APOC1 genetic markers associated with age of onset of Alzheimer's Disease | |
US20060177860A1 (en) | Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs | |
US20060183146A1 (en) | Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs | |
WO2010111080A2 (en) | Optimized treatment of schizophrenia | |
JP4575775B2 (ja) | 免疫抑制療法に際してのコレステロール上昇予知方法 | |
EP1673472B1 (en) | Use of genetic polymorphisms to predict drug-induced hepatotoxicity | |
US20070289889A1 (en) | Biomarkers For The Prediction Of Drug-In Duced Diarrhea | |
US20060178843A1 (en) | Genetic markers in the CSF2RB gene associated with an adverse hematological response to drugs | |
US9879324B2 (en) | Genetic determinants of prostate and breast cancer risk | |
WO2011147763A1 (en) | Biomarkers | |
JP2003528593A (ja) | 5−ヒドロキシトリプタミン輸送体遺伝子多型 | |
Berlin | Genetics/transcriptomics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |